Methods of treating lipedema including akr1c1 as a therapeutic target
AssigneeMagi Euregio Scs
InventorsMatteo Bertelli, Elena Manara, Paolo Enrico Maltese, Sandro Michelini, Serena Michelini, Maria Rachele Ceccarini, Pietro Chiurazzi, Karen Louise Herbst
Life of this patent
Estimating the term…
Abstract
The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.
Claims7
1) A method of treating and/or preventing of human lipedema in a subject, the method comprising administering or applying to a subject in need thereof a therapeutically effective amount of a compound of natural or synthetic origin suitable for modulating the activity of AKR1C1 or of prostaglandins, wherein the compound is an inhibitor of AKR1C1 or modulates the catalytic activity of the AKR1C1 enzyme, and comprises competitive inhibitors with a core structure of flavones.
3) A composition for the treatment of human lipedema in the form of a cream or ointment, comprising an inhibitor of AKR1C1 or a compound that modulates the catalytic activity of the AKR1C1 enzyme or of prostaglandins, wherein the inhibitor is a competitive inhibitor with a core structure of flavones.
Dependencies are inferred from the claim text.